Skip to content

Our Pipeline

WE ARE DEDICATED TO ADVANCING A NOVEL CLASS OF CONDITIONALLY-ACTIVATED PROINFLAMMATORY IMMUNE MODULATORS INTO CLINICAL DEVELOPMENT

Candidate
Lead ID
Lead Op
IND-Enabling
Clinic
WTX-124
  • WTX-124 is a systemically-delivered, conditionally-activated Interleukin-2 (IL-2) INDUKINETM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-2 therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in multiple tumor types.
  • Key features of WTX-124 include maintenance of full IL-2 potency, high affinity blockade of IL2 - IL2Rb/IL2Rg interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation.
  • In preclinical studies, WTX-124 exhibits excellent anti-tumor activity with a favorable pharmacokinetic and tolerability profile. Efficacy is driven by the differentiation, activation and expansion of T effector and memory lymphocyte immune responses.
WTX-330
  • WTX-330 is a systemically-delivered, conditionally-activated Interleukin-12 (IL-12) INDUKINETM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IL-12 therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors.
  • Key features of WTX-330 include high affinity blockade of IL-12 – IL-12R interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation.
  • In preclinical studies, WTX-330 exhibits excellent anti-tumor activity and a favorable pharmacokinetic and tolerability profile. Robust anti-tumor activity is mediated through stimulation of innate and adaptive antitumor immune responses - dendritic cell maturation and cross-presentation, T Helper 1 differentiation and amplification of antitumor T effector cell responses.
WTX-613
  • WTX-613 is a systemically-delivered, conditionally-activated Interferon alpha (IFNα) INDUKINETM molecule that is being developed to minimize the severe toxicities that have been observed with recombinant IFNα therapy and maximize clinical benefit when administered as monotherapy or in combination with checkpoint inhibitors in refractory and/or immunologically unresponsive tumors.
  • Key features of our INDUKINETM molecule include high efficiency blockade of IFNα – IFNR interaction in systemic circulation and non-tumor tissues, half-life extension for optimal tumor exposure and proprietary tumor-selective protease activation.
  • In preclinical studies, WTX-613 exhibits robust anti-tumor activity mediated through stimulation of a type I interferon immune response with excellent pharmacokinetics and tolerability.
Discovery
Programs
  • We apply our PREDATORTM protein engineering technology platform to identify, design, optimize and validate new immuno-oncology, autoimmune and inflammatory disease product candidates.